# A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial

> **NIH NIH R44** · AQUALUNG THERAPEUTICS CORP. · 2023 · $1,500,000

## Abstract

ABSTRACT
The serious unmet need to address the excessive mortality observed in patients with Acute Respiratory Distress
Syndrome (ARDS) has been brought sharply into focus by the current COVID-19 pandemic. In this R-44
application, Aqualung Therapeutics will address this therapeutic gap by utilizing a novel, humanized monoclonal
antibody, ALT-100 mAb, which binds/neutralizes a novel ARDS target, eNAMPT (extracellular nicotinamide
phosphoribosyltransferase), to reduce ARDS/VILI severity. We have shown that eNAMPT functions as a DAMP
(tissue damage-associated molecular pattern) that binds Toll-like receptor 4 (TLR4) to elicit profound NFkB-
driven inflammation, processes we have shown to be involved in pathobiology of ARDS and mechanical
ventilator-induced lung injury (VILI). Importantly, we demonstrated that eNAMPT is a highly druggable
ARDS target with the ALT-100 mAb profoundly attenuating the cytokine storm and inflammatory lung injury in
preclinical models of ARDS/VILI including a porcine model of septic shock-induced ARDS/VILI. We completed
GLP IND-enabling pharmacokinetic (PK) studies (T1/2 half-life of 12-14 days) and toxicity studies (rats/pigs)
which failed to identify any discernable level of toxicity even up to 50 mg/kg of ALT-100 mAb (28 day study).
Importantly, we have completed CMC and a 200L cGMP Bioreactor run (expression 6 gms/L) generating
sufficient mAb for completion of a first-in-human (FIH) Phase 1A safety ascending dose study clinical trial in
healthy volunteers (beginning June 2022) and the Phase 2 A safety/efficacy study called PUERTA (Pioneering
the Utility of eNAMPT-Reducing Therapies in ARDS/VILI) in ARDS subjects with sepsis, septic shock, trauma,
bacterial or viral pneumonia, or COVID-19 infection. We anticipate FDA Investigational New Drug approval in
Q2 2022 for the ALT-100 mAb as an ARDS therapeutic intervention. This R-44 award will support the PUERTA
P2A trial of ALT-100 mAb in 90 severely hypoxemic subjects (2:1, ALT-100:placebo) with the diagnosis of
moderate-to-severe ARDS (P/F <200) who are immediately treated with mechanical ventilation (MV), with high
flow nasal O2 (HFNO) or non-invasive ventilation (NIV i.e. BIPAP/CPAP). SA #1 will assess safety, tolerability,
and PK of ALT-100 mAb at 2 dose levels (1mg/kg or 4 mg/kg) compared to placebo. SA #2 will assess the
capacity for ALT-100 mAb to reduce ventilator requirements (# ventilator-free days), the incidence of multi-organ
failure (MOF), the need for MV in HFNO/NIV-treated ARDS subjects, and reductions in plasma cytokines i.e.
pharmacodynamic effects [PD] SA #3 will assess predictive capacity of plasma eNAMPT levels and NAMPT
SNPs in identifying PUERTA subjects who respond to single dose treatment with ALT-100. The R-44 PUERTA
trial, overseen by our CRO, Prevail Infoworks and conducted at 5 academic clinical sites, will directly address
the unmet need for novel ARDS therapies and confirm eNAMPT as a highly druggable therapeutic target for
ARDS. Successful a...

## Key facts

- **NIH application ID:** 10581161
- **Project number:** 2R44HL145930-04
- **Recipient organization:** AQUALUNG THERAPEUTICS CORP.
- **Principal Investigator:** Joe G. N. Garcia
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1,500,000
- **Award type:** 2
- **Project period:** 2019-06-01 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10581161

## Citation

> US National Institutes of Health, RePORTER application 10581161, A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial (2R44HL145930-04). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10581161. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*